← All quick references
ClearRounds Health · Cardiology · Quick Reference
Cardiovascular-Kidney-Metabolic / Cardiorenal Syndrome
PDF coming soon
Sleep, CKM & ComorbiditiesIntermediateIn progressOne-page PDF
CKM staging concepts, HF/CKD/diabetes overlap, SGLT2i, RAAS/MRA considerations, diuretic monitoring, and renal safety pearls.
Last reviewed
Pending initial clinical review
Sources / guidelines to verify
- 2023 AHA Presidential Advisory: Cardiovascular-Kidney-Metabolic (CKM) Health
- 2023 KDIGO Diabetes & CKD Guideline
- Local renal-dosing & electrolyte monitoring protocols
Disclaimer: Educational reference only. Not a substitute for clinician judgment, local protocols, or current guideline review.
One-page reference
Draft content pending the site owner’s clinical review. Verify against the sources above and local protocol before clinical use.
1
What it is / why it matters
- Overlapping cardiovascular–kidney–metabolic dysfunction (CKM syndrome), staged 0–4.
- Cardiorenal syndrome = bidirectional heart–kidney deterioration.
- Treating the axis together — not one organ at a time — improves outcomes.
2
Key diagnostic clues
- Coexisting obesity/metabolic syndrome, CKD (low eGFR or albuminuria), diabetes, HF, and ASCVD.
- Worsening renal function during decongestion, or congestion resistant to diuretics.
3
Initial workup
- BMP/eGFR, urine albumin:creatinine, HbA1c, lipids, BP, weight/BMI.
- BNP/NT-proBNP if heart failure is suspected; assign a CKM stage.
4
Management framework
- SGLT2 inhibitors — cardio-renal protection across HF, CKD, and diabetes (foundational).
- GLP-1 receptor agonist for weight and CV risk in obesity/diabetes.
- RAAS blockade (ACEi/ARB) for albuminuric CKD / HTN.
- Finerenone (MRA) for diabetic CKD with albuminuria.
- Diuretics for congestion with close electrolyte and renal monitoring; statin per ASCVD risk; BP <130/80.
5
Red flags / escalate now
- Rapidly rising creatinine, refractory hyperkalemia, or diuretic-resistant congestion.
- Acute kidney injury → cardiology–nephrology co-management.
6
Follow-up / monitoring
- BMP after starting/adjusting RAAS, MRA, diuretic, or SGLT2i.
- Track weight, BP, and albuminuria over time.
7
Clinic pearls
- An initial eGFR dip when starting SGLT2i or RAAS therapy is expected and protective long-term — don’t stop reflexively.
- Finerenone targets albuminuric diabetic CKD; treat the axis, not a single organ.
Related tools
Related quick references
Suggest an edit or request this reference
Spot something to improve, or want this one-pager prioritized? Send feedback to the ClearRounds Health team.
Share feedback →